Your browser doesn't support javascript.
loading
Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer.
Günther, Maximilian; Schuler, Markus; Hentschel, Leopold; Salm, Hanna; Schmitz, Marie-Therese; Jaehde, Ulrich.
Affiliation
  • Günther M; Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.
  • Schuler M; Onkologischer Schwerpunkt am Oskar-Helene-Heim, 14195 Berlin, Germany.
  • Hentschel L; Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, 01307 Dresden, Germany.
  • Salm H; Division of Hematology, Oncology and Stem Cell Transplantation, Medical Clinic I, Department of Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, 01307 Dresden, Germany.
  • Schmitz MT; Klinik und Poliklinik für Innere Medizin C, Universitätsmedizin Greifswald, 17489 Greifswald, Germany.
  • Jaehde U; Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany.
Cancers (Basel) ; 16(11)2024 May 31.
Article in En | MEDLINE | ID: mdl-38893228
ABSTRACT

BACKGROUND:

We aimed to assess medication risks and determine factors influencing the health-related quality of life (HRQOL) in cancer inpatients.

METHODS:

A retrospective analysis was conducted to identify drug-related problems (DRPs) based on medication reviews, including patient-reported outcomes (PROs). Multiple linear regression analyses were performed to identify sociodemographic, disease-related, and drug therapy-related factors influencing changes from hospital admission to discharge in the scales of the EORTC QLQ-C30 questionnaire.

RESULTS:

A total of 162 inpatients with various hematological and solid cancer diseases was analyzed. Patients received a mean of 11.6 drugs and 92.6% of patients exhibited polymedication resulting in a mean of 4.0 DRPs per patient. Based on PRO data, 21.5% of DRPs were identified. Multiple linear regression models described the variance of the changes in global HRQOL and physical function in a weak-to-moderate way. While drug therapy-related factors had no influence, relapse status and duration of hospital stay were identified as significant covariates for global HRQOL and physical function, respectively.

CONCLUSION:

This analysis describes underlying DRPs in a German cancer inpatient population. PROs provided valuable information for performing medication reviews. The multiple linear regression models for global HRQOL and physical function provided explanations for changes during hospital stay.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2024 Document type: Article Affiliation country: Alemania Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2024 Document type: Article Affiliation country: Alemania Country of publication: Suiza